Gina Petroni, Ph.D.

Gina Petroni, Ph.D.

Professor
Director, Division of Translational Research & Applied Statistics

Ph.D., University of Michigan

P.O. Box 800717
Tel: 1-434-924-8363
Fax: 1-434-243-5999
Email: gpetroni@virginia.edu
OMS Room 3885

Expertise:

Design, analysis and monitoring of cancer clinical trials.

Research Interests:

Dr. Petroni's areas of research interest include: early phase and vaccine clinical trials in oncology. Dr. Petroni is the Director of the Biostatistic Shared Resource for the UVa Cancer Center.

Recent Publications

Slingluff CL, Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA. (2009) Effect of GM-CSF on circulating CD8+ and CD4+ T cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial. Clinical Cancer Research, Nov 15;15(22):7036-44. Epub 2009 Nov 10. PMID: 19903780.

 

Cavaliere R, Petroni G, Lopes MB, Schiff D; (2010) The International Primary Central Nervous System Lymphoma Collaborative Group. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 116(4):863-70 Feb 15. PMID: 20052713.

 

Jones DR, Taylor MD, Petroni GR, Shu J, Burks SG, Daniel TM, Gillenwater HH. (2010) Phase I Trial of Intrapleural Docetaxel Administered Through an Implantable Catheter in Subjects with a Malignant Pleural Effusion. J Thoracic Oncology, 5(1):75-81. PMID: 19884858.

 

Slingluff CL. Petroni GR. Smolkin ME. Chianese-Bullock KA. Smith K. Murphy C. Galeassi N. Neese PY. Grosh WW. Nail CJ. Ross M. von Mehren M. Haas N. Boisvert ME. Kirkwood JM. (2010) Immunogenicity for CD8+ and CD4+ T Cells of 2 Formulations of an Incomplete Freund's Adjuvant for Multipeptide Melanoma Vaccines. Journal of Immunotherapy. 33(6):630-8. PMID: 20551833.

 

Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, Sargent DJ, Benedetti J, Wickerham DL, Djulbegovic B, Slingluff CL Jr. (2010) Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clinical Trials. 7(4):312-21. PMID: 20595245.